-
Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
Akolekar R, Pérez Penco JM, Skyfta E, Rodríguez Calvo J, Nicolaides KH.
Fetal Diagn Ther 2010;27:72-7. -
Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia.
Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH.
Prenat Diagn 2009;29:1103-8. -
Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysis.
Yu CKh, Casas JP, Savvidou MD, Sahemey MK, Nicolaides KH, Hingorani AD.
BMC Pregnancy Childbirth 2006;6:7. -
A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound.
Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS.
Ultrasound Obstet Gynecol 2006;27:13-7. -
Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy.
Savvidou MD, Vallance PJ, Nicolaides KH, Hingorani AD.
Hypertension 2001;38:1289-93. -
Exhaled nitric oxide concentration and amniotic fluid nitrite concentration during pregnancy.
Morris-NH, Carroll S, Nicolaides KH, Steer PJ, Warren JB.
Eur J Clin Invest 1995;25:138-41.